Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Isenberg

Showing results (171-180 of 280) with videos related to

Pageof 28
Sort By:
Immunity|January 19, 2010
CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patientsPaul A Blair, Lina Yassin Noreña, Fabian Flores-Borja, et al.
The Journal of Rheumatology|December 1, 2004
Defining response in systemic lupus erythematosus: a study by the Systemic Lupus International Collaborating Clinics groupSean J Wollaston, Vernon T Farewell, David A Isenberg, et al.
Rheumatology (Oxford, England)|January 6, 2010
Long-term improvement of lipid profile in patients with refractory systemic lupus erythematosus treated with B-cell depletion therapy: a retrospective observational studyJosé M Pego-Reigosa, Tim Y-T Lu, Manuela F Fontanillo, et al.
Rheumatology (Oxford, England)|September 23, 2020
Anti-protein C antibodies and acquired protein C resistance in SLE: novel markers for thromboembolic events and disease activity?Giuseppe A Ramirez, Ian Mackie, Susanna Nallamilli, et al.
Molecular Immunology|October 18, 2003
Anti-cardiolipin/beta-2 glycoprotein activities co-exist on human anti-DNA antibody light chainsSanjeev Kumar, Sylvia Nagl, J K Kalsi, et al.
Molecular Immunology|October 19, 2004
Beta-2-glycoprotein specificity of human anti-phospholipid antibody resides on the light chain: a novel mechanism for acquisition of cross-reactivity by an autoantibodySanjeev Kumar, Sylvia Nagl, Jatinderpal K Kalsi, et al.
Arthritis and Rheumatism|April 1, 2009
A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patientsTim Y-T Lu, Kristine P Ng, Geraldine Cambridge, et al.
Arthritis and Rheumatism|November 1, 2008
Reliability and validity of the myositis disease activity assessment toolShabina M Sultan, Elizabeth Allen, Chester V Oddis, et al.
Molecular Immunology|August 12, 2003
Relative importance of different human aPL derived heavy and light chains in the binding of aPL to cardiolipinIan P Giles, Joanna Haley, Sylvia Nagl, et al.
BMJ Open|December 19, 2019
Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trialAlexis Jones, Patrick Muller, Caroline J Dore, et al.
Pageof 28

Showing results (171-180 of 280) with videos related to

Sort By:
Pageof 28
Immunity|January 19, 2010
CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patientsPaul A Blair, Lina Yassin Noreña, Fabian Flores-Borja, et al.
The Journal of Rheumatology|December 1, 2004
Defining response in systemic lupus erythematosus: a study by the Systemic Lupus International Collaborating Clinics groupSean J Wollaston, Vernon T Farewell, David A Isenberg, et al.
Rheumatology (Oxford, England)|January 6, 2010
Long-term improvement of lipid profile in patients with refractory systemic lupus erythematosus treated with B-cell depletion therapy: a retrospective observational studyJosé M Pego-Reigosa, Tim Y-T Lu, Manuela F Fontanillo, et al.
Rheumatology (Oxford, England)|September 23, 2020
Anti-protein C antibodies and acquired protein C resistance in SLE: novel markers for thromboembolic events and disease activity?Giuseppe A Ramirez, Ian Mackie, Susanna Nallamilli, et al.
Molecular Immunology|October 18, 2003
Anti-cardiolipin/beta-2 glycoprotein activities co-exist on human anti-DNA antibody light chainsSanjeev Kumar, Sylvia Nagl, J K Kalsi, et al.
Molecular Immunology|October 19, 2004
Beta-2-glycoprotein specificity of human anti-phospholipid antibody resides on the light chain: a novel mechanism for acquisition of cross-reactivity by an autoantibodySanjeev Kumar, Sylvia Nagl, Jatinderpal K Kalsi, et al.
Arthritis and Rheumatism|April 1, 2009
A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patientsTim Y-T Lu, Kristine P Ng, Geraldine Cambridge, et al.
Arthritis and Rheumatism|November 1, 2008
Reliability and validity of the myositis disease activity assessment toolShabina M Sultan, Elizabeth Allen, Chester V Oddis, et al.
Molecular Immunology|August 12, 2003
Relative importance of different human aPL derived heavy and light chains in the binding of aPL to cardiolipinIan P Giles, Joanna Haley, Sylvia Nagl, et al.
BMJ Open|December 19, 2019
Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trialAlexis Jones, Patrick Muller, Caroline J Dore, et al.
Pageof 28